Effect of a Lifestyle-Focused Web-Based Application on Risk Factor Management in Patients Who Have Had a Myocardial Infarction: Randomized Controlled Trial

Halldóra Ögmundsdóttir Michelsen1,2, PhD; Ingela Sjölin3, MA; Maria Bäck4,5, PhD; Manuel Gonzalez Garcia6,7, PhD; Anneli Olsson8,9, MSc; Camilla Sandberg6,10, PhD; Alexandru Schiopu1,11, PhD; Margrét Leósdóttir1,3, PhD

1Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
2Department of Internal Medicine, Helsingborg Hospital, Helsingborg, Sweden
3Department of Cardiology, Skane University Hospital, Malmö, Sweden
4Department of Health, Medicine and Caring Sciences, Unit of Physiotherapy, Linköping University, Linköping, Sweden
5Department of Occupational Therapy and Physiotherapy, Sahlgrenska University Hospital, Gothenburg, Sweden
6Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden
7Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia
8Department of Cardiology, Skane University Hospital, Lund, Sweden
9Department of Clinical Sciences, Lund University, Lund, Sweden
10Department of Community Medicine and Rehabilitation, Physiotherapy, Umeå University, Umeå, Sweden
11Department of Internal Medicine, Skane University Hospital, Lund, Sweden

Corresponding Author:
Halldóra Ögmundsdóttir Michelsen, PhD
Department of Clinical Sciences Malmö
Lund University
Jan Waldenströms Gata 35
Malmö, 205 02
Sweden
Phone: 46 4061000
Email: halldora.michelsen@med.lu.se

Abstract

Background: Cardiac rehabilitation is central in reducing mortality and morbidity after myocardial infarction. However, the fulfillment of guideline-recommended cardiac rehabilitation targets is unsatisfactory. eHealth offers new possibilities to improve clinical care.

Objective: This study aims to assess the effect of a web-based application designed to support adherence to lifestyle advice and self-control of risk factors (intervention) in addition to center-based cardiac rehabilitation, compared with cardiac rehabilitation only (usual care).

Methods: All 150 patients participated in cardiac rehabilitation. Patients randomized to the intervention group (n=101) received access to the application for 25 weeks where information about lifestyle (eg, diet and physical activity), risk factors (eg, weight and blood pressure [BP]), and symptoms could be registered. The software provided feedback and lifestyle advice. The primary outcome was a change in submaximal exercise capacity (Watts [W]) between follow-up visits. Secondary outcomes included changes in modifiable risk factors between baseline and follow-up visits and uptake and adherence to the application. Regression analysis was used, adjusting for relevant baseline variables.

Results: There was a nonsignificant trend toward a larger change in exercise capacity in the intervention group (n=66) compared with the usual care group (n=40; +14.4, SD 19.0 W, vs +10.3, SD 16.1 W; P=.22). Patients in the intervention group achieved significantly larger BP reduction compared with usual care patients at 2 weeks (systolic −27.7 vs −16.4 mm Hg; P=.006) and at 6 to 10 weeks (systolic −25.3 vs −16.4 mm Hg; P=.02, and diastolic −13.4 vs −9.1 mm Hg; P=.05). A healthy diet index score improved significantly more between baseline and the 2-week follow-up in the intervention group (+2.3 vs +1.4 points; P=.05), mostly owing to an increase in the consumption of fish and fruit. At 6 to 10 weeks, 64% (14/22) versus 46% (5/11) of smokers in the intervention versus usual care groups had quit smoking, and at 12 to 14 months, the respective percentages were 55%
(12/22) versus 36% (4/11). However, the number of smokers in the study was low (33/149, 21.9%), and the differences were nonsignificant. Attendance in cardiac rehabilitation was high, with 96% (96/100) of patients in the intervention group and 98% (48/49) of patients receiving usual care only attending 12- to 14-month follow-up. Uptake (logging data in the application at least once) was 86.1% (87/101). Adherence (logging data at least twice weekly) was 91% (79/87) in week 1 and 56% (49/87) in week 25.

**Conclusions:** Complementing cardiac rehabilitation with a web-based application improved BP and dietary habits during the first months after myocardial infarction. A nonsignificant tendency toward better exercise capacity and higher smoking cessation rates was observed. Although the study group was small, these positive trends support further development of eHealth in cardiac rehabilitation.

**Trial Registration:** ClinicalTrials.gov NCT03260582; https://clinicaltrials.gov/ct2/show/NCT03260582

**International Registered Report Identifier (IRRID):** RR2-10.1186/s13063-018-3118-1

(J Med Internet Res 2022;24(3):e25224) doi: 10.2196/25224

**KEYWORDS**
eHealth; cardiac rehabilitation; cardiovascular; mobile device app; risk factors; web-based application; mobile phone

**Introduction**

**Background**

Mortality rates from coronary heart disease (CHD) have decreased in the last decades [1-3]. However, the falling mortality rates have led to an increased number of survivors who need support in the secondary prevention of recurrent coronary events [3,4]. Comprehensive cardiac rehabilitation programs, which are multidisciplinary medical and health behavioral interventions, effectively reduce CHD morbidity and mortality [3-7]. International guidelines strongly recommend participation in cardiac rehabilitation and have set therapeutic goals on risk factor and lifestyle management [7]. Cardiac rehabilitation goals include smoking cessation, medical management of low-density lipoprotein (LDL)-cholesterol and blood pressure (BP), maintaining a healthy diet, and participation in an exercise training program, also referred to as exercise-based cardiac rehabilitation [7]. Despite clear set goals, both attendance to cardiac rehabilitation and therapeutic goal attainment are suboptimal [8,9].

Cardiac rehabilitation programs in Sweden hold a high standard compared with European counterparts when it comes to providing guideline-recommended services [10]. Moreover, in 2019, the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry reported that after participating in a 1-year long cardiac rehabilitation program, patients who had an myocardial infarction (MI) only reached target levels for LDL-cholesterol in about 60% of cases, only 55% of smokers were abstinent and 19% of patients had participated in exercise-based cardiac rehabilitation programs [9]. A lack of reaching therapeutic goals while offering guideline-recommended services indicates that alternative methods may be needed to improve patient outcomes.

Previous studies on eHealth cardiac rehabilitation have resulted in noninferiority or concluded that patients benefited with regard to lifestyle changes and risk factor management [11-20]. However, these studies have varied in sample size and follow-up time, and more studies are needed. eHealth is of interest to the field of cardiac rehabilitation because it has the potential to overcome some known barriers to participation, such as geographical distance, communication barriers, and rigid follow-up structures, and to individualize cardiac rehabilitation programs [4,21].

**Objectives**

The aim of this study is to evaluate the efficacy of a web-based application as an addition to a comprehensive center-based cardiac rehabilitation program, in comparison with usual care center-based cardiac rehabilitation only. The web-based application was designed to support adherence to lifestyle advice and self-control of risk factors in patients who had an MI. In the planning phase of our study, we predicted that the web-based application would primarily affect patients’ lifestyle and with that increased physical activity levels and exercise capacity [22]. The benefits of increased physical activity levels and participation in exercise-based cardiac rehabilitation are largely mediated through an increase in physical fitness. Submaximal exercise capacity is an objective measurement of physical fitness and was, therefore, chosen as the primary outcome [23].

**Methods**

**Trial Design and Framework**

The protocol, which followed the principles outlined in the Declaration of Helsinki, was approved by the Regional Ethical Review Board at Lund University (approval 2016/5). The protocol has been previously described in detail [22] and is summarized here.

We conducted an unblinded parallel multicenter randomized controlled trial (RCT) at 3 cardiac rehabilitation centers based at university hospitals in Sweden. At the time of the study, approximately 1200 patients aged <75 years were treated for acute MI at the 3 study centers each year.

**Participants, Recruitment, and Randomization**

The inclusion criteria were age 18-74 years, having had an MI within the last 2 weeks, owning a smartphone or having access to the internet via a computer or tablet, and being able to handle the software. The exclusion criteria were having an expected...
survival of <1 year, dementia, severe psychiatric illness or drug abuse, severe physical disability limiting the patients’ ability to participate in a center-based exercise-based cardiac rehabilitation, inability to speak or understand the Swedish language, and a 3-vessel or left main disease requiring coronary artery bypass grafting. The age criterion was set to match that applied by the SWEDHEART registry.

Eligibility screening and study inclusion were performed within 2 weeks of an index MI while participants were admitted to a coronary care unit at each participating hospital. Local study coordinators (physicians, nurses, or physiotherapists) provided eligible patients with information about the study, offered participation, and obtained written informed consent. Once included in the study, the participants were randomized to 1 of the 2 study arms using opaque sealed envelopes. The envelopes, which included information on which study group the participant would be randomized to, were prepared by a member of the research team and shuffled by another member. The envelopes were thereafter sequentially numbered with unique numbers for each recruiting site. Upon recruitment, baseline questionnaires were administered.

**Usual Care**

Participants in both arms of the study were offered participation in a comprehensive cardiac rehabilitation program at each center. A description of the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) figure on the content of each follow-up visit is available in the protocol [22]. In short, the cardiac rehabilitation programs consisted of five outpatient follow-up visits: 3 visits with a nurse or physician and 2 visits with a physiotherapist (Figure 1).

**The Intervention**

Participants randomized to the intervention group of the study received access to the LifePod web-based mobile device app (Cross Technology Solutions AB) for the first 25 weeks of the cardiac rehabilitation program. The LifePod software contained two separate interfaces: one for the patient and one for the treating health care professionals (Figure 2). In the patient interface, the patient could log information about diet, physical activity and exercise, weight, heart rate, BP, and smoking, as well as symptoms and intake of medication. The patient could compare his or her own data to guideline-recommended targets and received automated positive feedback on healthy lifestyle choices as well as general recommendations on exercise, daily physical activity, and healthy diet. In the medical interface assessed by the treating cardiac rehabilitation staff, the system ranked patients, giving high priority to, for example, patients reporting chest pain or out-of-range BP measurements. The medical interface was reviewed twice a week by a nurse.

---

**Figure 1.** The follow-up of the patients who have had a myocardial infarction, in the study.

| Index event          | Approximately 2 weeks | 2-4 weeks | 6-10 weeks | 4-6 months | 12-14 months |
|----------------------|-----------------------|-----------|------------|------------|--------------|
| Eligibility screening, informed consent, study enrollment and allocation. | Initial assessment with a nurse, control of risk factors and lifestyle counselling. | First follow-up visit with a physiotherapist, submaximal exercise test, physical activity counselling and exercise prescription. | Second follow-up visit with a nurse or physician, control of risk factors and lifestyle counselling. | Second follow-up visit with a physiotherapist, submaximal exercise test, physical activity counselling and exercise prescription. | Third follow-up visit with a nurse, control of risk factors and lifestyle counselling. |

**Figure 2.** The life pod mobile device app.
Data Collection

Patient outcomes were derived from the SWEDHEART registry. The SWEDHEART registry is a nationwide quality registry that records baseline characteristics, treatments, follow-up, and outcome data of patients who have had an MI [9]. Data collection started at the time of index MI and continued at all follow-up visits, as shown in Figure 1. The time points for data collection were prespecified in accordance with standardized SWEDHEART registry follow-up visits. Information was collected using standardized forms that can be downloaded from the SWEDHEART registry webpage [24].

At the physiotherapist visits at 2 to 4 weeks and 4 to 6 months, a submaximal exercise test on a bicycle ergometer was performed [25,26]. During the test, heart rate, systolic BP (SBP), perceived exertion, dyspnea, and chest pain were registered according to the Borg rating of perceived exertion and category ratio-10 scales [27]. The test was discontinued at Borg rating of perceived exertion 17, dyspnea 7 on the Borg category ratio-10 scale, or other routine discontinuation criteria for exercise stress testing, including, for example, chest pain and fall in SBP. At the first visit, the patients received individualized physical activity and exercise recommendations and were invited to participate in exercise-based cardiac rehabilitation as a part of their comprehensive cardiac rehabilitation program.

The follow-up visits with a nurse or physician at approximately 2 weeks, 6 to 10 weeks, and 12 to 14 months focused on risk factors and lifestyle. Fasting plasma glucose (mmol/L), hemoglobin A1c (mmol/mol), and plasma lipids (total cholesterol, LDL-cholesterol, high-density lipoprotein–cholesterol, and triglycerides; mmol/L) samples were drawn and analyzed using accredited methods at each hospital. BP was measured using a manual sphygmomanometer after a 5-minute rest with the patient in a sitting position. Weight (kg) was measured in light indoor clothing, and BMI (kg/m²) was calculated. Smoking status was self-reported. At baseline, 6 to 10 weeks, and 12 to 14 months, smoking abstinence was defined as being smoke-free for ≥1 month. At the 2-week visit, abstinence was defined as being abstinent at the time of the visit. Diet was evaluated using a 4-item questionnaire adapted from the national guidelines for the management of unhealthy lifestyle in the general population [28]. The questions aim to quantify the amount of vegetables, fruit, fish, and sweets consumed. Each question had 4 possible answers, giving 0 to 3 points. The scores for each question were subsequently added, forming the healthy diet index (0-12 points). Levels of physical
activity were self-reported using 2 sets of questionnaires. Haskell questions on physical activity and exercise evaluated both the number of days during the last week [1-7] with at least 30 minutes of physical activity and the number of days during the last week [1-7] with at least 20 minutes of exercise training [29]. The Frändin-Grimby physical activity questionnaire aims to evaluate the level of physical activity a person achieved in the last week on a scale of 1 to 6, with 1 being hardly any physical activity and 6 being regular strenuous physical activity [30].

The data that support this study’s findings are available from the Uppsala Clinical Research Centre, Sweden. The primary responsibility for data monitoring, including data sharing, integrity, and security, was assigned to the principal investigator and local study coordinators. The trial was conducted according to Good Clinical Practice, and data were handled according to the Swedish Data Protection Authority and General Data Protection Regulations.

Statistical Methods and Outcomes

With a power of 90%, a 2-sided significance level of .05, and a mean difference of at least 10 (SD 20) W among the groups, the estimated sample size needed was 50 participants in each group [22]. However, the expected loss of adherence to the web-based application led to the formation of an unequal allocation ratio of 1:2 in the usual care group versus intervention group.

The primary outcome was the change (δ value) in submaximal exercise capacity, measured in Watts, between 2 submaximal exercise tests performed at 2 to 4 weeks and at 4 to 6 months. The secondary outcomes were changes (δ values) in dietary habits and physical activity, as well as SBP and diastolic BP (DBP), total cholesterol, LDL-cholesterol, high-density lipoprotein–cholesterol, triglycerides, fasting plasma glucose, hemoglobin A1c, and BMI. The secondary outcomes also included smoking status and uptake and adherence to the web-based application. Uptake was defined as the proportion of patients who logged on to the patient interface at least once, and adherence was defined as the proportion of patients registering data at least twice per week on a weekly basis throughout the 25-week intervention period. An additional analysis on the difference in mortality and number of hospital readmissions during the trial period was performed. Baseline characteristics are presented as means (SDs) for normally distributed continuous variables, medians (IQR) for nonnormally distributed continuous variables, and as numbers and percentages for categorical variables. Variable distribution was assessed by visual inspection of histograms and Q–Q plots and by calculating skewness and kurtosis; z values between −1.96 and 1.96 were used to define the normally distributed interval. To compare outcome measures of continuous variables among the groups, a 2-tailed Student t test or a Mann–Whitney U test was performed. A univariate analysis of variance, adjusting for age, gender, weight, previous CHD, and smoking status at index MI was also performed. In the analysis of variance, the dependent variables were the measured outcomes, and the independent variables were the intervention and chosen covariates. For categorical variables, a chi-square test and a logistic regression analysis adjusting for the previously mentioned covariates were used. For within-group comparisons, a paired t test was used for normally distributed variables and a Wilcoxon signed-rank test for skewed data. For all analyses, an α level of .05, and 2-tailed testing was used. Individuals with missing data on covariates or outcome variables were excluded from the analysis (listwise exclusion). All data were analyzed by using the SPSS (version 25.0; IBM Corp).

Results

Participant Recruitment and Flow

Of the 281 patients assessed for eligibility, 150 (53.4%) consented and indicated intent to attend cardiac rehabilitation and, if allocated to the intervention group, use the web-based application (Figure 3). In total, 32.7% (49/150) of the patients were allocated to the control group and 67.3% (101/150) to the intervention group. At the end of the study period, 1 participant in each group of the study had died. For 1 patient, the index event diagnosis changed during follow-up from MI to cardiac amyloidosis, and the patient was excluded from the analysis. Of the 150 patients, 3 (2%) did not attend their follow-up visits at 12 to 14 months after MI and were classified as lost to follow-up.
Patient inclusion started in April 2016 and was finalized in April 2018. The follow-up period was completed in June 2019.

**Baseline Characteristics**

Baseline characteristics are presented in Table 1. The intervention group had a slightly higher prevalence of cardiac comorbidities at baseline including a higher mean SBP and were more often taking cardioprotective medication compared with the usual care group. In addition, a proportionally higher number of patients in the intervention group had an ST elevation MI.
Table 1. Baseline characteristics.a

| Parameters                                      | Intervention (n=100) | Usual care (n=49) |
|------------------------------------------------|---------------------|-------------------|
| Age (years), mean (SD)                         | 60.0 (8.9)          | 61.1 (8.6)        |
| Male gender, n (%)                             | 84 (84)             | 36 (73)           |
| Active smoker, n (%)                           | 22 (22)             | 11 (22)           |
| **Physiological measures**                     |                     |                   |
| SBPb (mm Hg), mean (SD)                        | 150.0 (27.6)        | 142.9 (25.5)      |
| DBPc (mm Hg), mean (SD)                        | 88.5 (14.6)         | 86.8 (14.8)       |
| Waist circumference (cm), mean (SD)            | 104.9 (12.9)        | 104.5 (13.9)      |
| Weight (kg), mean (SD)                         | 86.3 (15.1)         | 85.3 (16.2)       |
| BMI (kg/m²), median (IQR)                      | 27 (25-30)          | 27 (25-29)        |
| **Laboratory measures**                        |                     |                   |
| Total cholesterol (mmol/L), mean (SD)          | 4.7 (1.1)           | 4.9 (1.1)         |
| LDLd-cholesterol (mmol/L), mean (SD)           | 2.8 (0.9)           | 3.0 (1.0)         |
| Triglycerides (mmol/L), median (IQR)           | 1.4 (0.9-2.1)       | 1.4 (1.0-1.9)     |
| HDLe-cholesterol (mmol/L), median (IQR)        | 1.2 (0.9-1.4)       | 1.2 (0.9-1.4)     |
| Fasting plasma glucose (mmol/L), median (IQR)  | 7.5 (6.4-9.2)       | 7.1 (6.2-8.9)     |
| HbA1cf (mmol/mol), median (IQR)                | 38 (34.5-41.0)      | 39 (36.0-42.0)    |
| **Previous disease, n (%)**                    |                     |                   |
| Ischemic heart disease (previous MIg, PCIh, or CABGi) | 18 (18)            | 6 (12)            |
| Heart failure                                  | 5 (5)               | 0 (0)             |
| Diabetes mellitus                              | 9 (9)               | 6 (12)            |
| Hypertension                                   | 42 (42)             | 17 (34)           |
| **Medication on hospital admission, n (%)**    |                     |                   |
| ACEi or ARBk                                   | 36 (36)             | 12 (24)           |
| Statins                                        | 24 (24)             | 5 (10)            |
| Acetylsalicylic acid                           | 18 (18)             | 5 (10)            |
| β-blockers                                     | 19 (19)             | 7 (14)            |
| **Medication at hospital discharge, n (%)**    |                     |                   |
| ACEi or ARB                                    | 95 (95)             | 46 (93)           |
| Statins                                        | 100 (100)           | 47 (95)           |
| DAPTl                                         | 100 (100)           | 49 (100)          |
| β-blockers                                     | 89 (89)             | 43 (87)           |
| **Type of MI, n (%)**                          |                     |                   |
| STEMIg                                         | 59 (59)             | 24 (48)           |
| NSTEMIh                                        | 41 (41)             | 24 (48)           |

aData are presented as n (%), mean (SD), or median (IQR).
bSBP: systolic blood pressure.
cDBP: diastolic blood pressure.
dLDL: low-density lipoprotein.
eHDL: high-density lipoprotein.
fHbA1C: glycated hemoglobin A1C.

https://www.jmir.org/2022/3/e25224
MI: myocardial infarction.
PCI: percutaneous coronary intervention.
CABG: coronary artery bypass grafting.
ACEi: angiotensin-converting enzyme inhibitor.
ARB: angiotensin II receptor blocker.
DAPT: dual antiplatelet therapy.
STEMI: ST elevation myocardial infarction.
NSTEMI: non-ST elevation myocardial infarction.

Primary Outcome
Because of missing data at the first or second follow-up with a physiotherapist, only 82% (40/49) of participants in the usual care group and 66% (66/100) in the intervention group qualified for analyses of the primary outcome.

Both groups increased their submaximal exercise capacity significantly between the first and second follow-up measurements (Figure 4). The intervention group increased their exercise capacity from 96.3 (SD 29.4) W to 110.8 W (SD 33.7 W; \(P<.001\)) and the corresponding values for the usual care group were 96.1 (SD 33.7) W to 106.5 W (SD 37.3 W; \(P<.001\)).

Figure 4. A boxplot of the change in submaximal exercise capacity in the intervention group and the usual care group. The difference in change in exercise capacity among the groups was nonsignificant.

There was no significant difference in the change in exercise capacity between the intervention group and the usual care group (+14.4, SD 19.0 W vs +10.3, SD 16.1 W; crude 95% CI −11.2 to 3.0, \(P=.26\); adjusted 95% CI −12.0 to 2.8, \(P=.22\)) at follow-up. The variation in the observed difference fell within the expected limits of +20 W to −20 W.

Secondary Outcomes
The secondary outcomes are shown in Tables 2-4. Crude analyses showed that at the 2-week follow-up, there was a significantly larger decrease in SBP in the intervention group than that in the usual care group. SBP remained lower in the intervention group than in the usual care group for the remainder of the follow-ups; however, the difference among the groups was nonsignificant. In the adjusted analysis, the decrease in SBP was significantly larger in the intervention group between baseline and 2 weeks and for both SBP and DBP between baseline and 6 to 10 weeks (Figure 5).
Table 2. Secondary outcome measures at the 2-week follow-up.a

| Characteristics               | Intervention Values | Change from baseline | Usual care Values | Change from baseline | P value for difference crude | P value for difference adjustedb |
|-------------------------------|---------------------|----------------------|-------------------|----------------------|-------------------------------|---------------------------------|
| Risk factors                  |                     |                      |                   |                      |                               |                                 |
| SBPc (mm Hg), mean (SD)       | 123.4 (17.4)        | −27.7 (27.6)         | 127.3 (13.9)      | −16.4 (24.1)         | .02                           | .006                            |
| DBPd (mm Hg), mean (SD)       | 76.0 (10.4)         | −13.1 (13.0)         | 76.1 (10.2)       | −11.1 (15.1)         | .43                           | .40                             |
| BMI (kg/m²), median (IQR)     | 27.1 (24.6 to 31.7) | −0.3 (−0.9 to 0.5)   | 27.8 (24.8 to 30.8) | −0.1 (−0.7 to 0.6)  | .34                           | .77e                            |
| Self-reported parameters, mean (SD) |                     |                      |                   |                      |                               |                                 |
| Vegetable consumption         | 2.2 (0.9)           | 0.4 (0.9)            | 2.2 (1.0)         | 0.4 (0.8)            | .81                           | .94                             |
| Fruit consumption             | 2.3 (0.7)           | 0.7 (1.0)            | 2.2 (0.9)         | 0.2 (1.0)            | .03                           | .03                             |
| Fish consumption              | 1.9 (1.0)           | 0.8 (1.0)            | 1.7 (1.0)         | 0.4 (0.8)            | .03                           | .02                             |
| Consumption of sweets         | 2.4 (0.8)           | 0.5 (0.9)            | 2.4 (0.7)         | 0.5 (0.9)            | .99                           | .99                             |
| Healthy diet index            | 8.7 (2.1)           | 2.3 (2.1)            | 8.3 (2.1)         | 1.4 (2.3)            | .05                           | .03                             |

aNumbers are presented as mean (SD), median (q1, q3), and P values. Crude and adjusted P values are shown for the differences in mean or median change (δ) between baseline and 2-week follow-up, comparing the intervention and usual care groups.
bAdjusted for gender, age, weight, previous heart disease, and smoking status at the time of the index event.
cSBP: systolic blood pressure.
dDBP: diastolic blood pressure.
eNot adjusted for weight.

The healthy diet index scores improved to a significantly larger extent between baseline and the 2-week follow-up in the intervention group than in the usual care group, mostly because of an increase in the consumption of fish and fruit (Table 2). However, this improvement was not sustained for the rest of the follow-up period (Tables 3 and 4).

There were no significant differences in self-reported physical activity among the groups. Results from the Haskell questions on physical activity and exercise [29] showed a mean change in number of days of performing at least 30 minutes of physical activity between baseline and the first follow-up with a physiotherapist at 2 to 4 weeks, which was 3.1 days (SD 2.2 days) for the intervention group and 2.5 days (SD 2.3 days) for the usual care group (adjusted P=.13). The corresponding numbers between baseline and the second follow-up with a physiotherapist at 4 to 6 months visit was 0.6 (SD 1.2) in the intervention group and 0.8 (SD 1.1) in the usual care group (adjusted P=.46).

According to the Frändin-Grimby physical activity questionnaire [30], the mean change in the level of physical activity a person achieved in the last week between baseline and the first follow-up with a physiotherapist at 2 to 4 weeks was 0.1 (SD 1.0) point in the intervention group and 0.3 (SD 1.0) point for the usual care group (adjusted P=.21). The mean change between baseline and the second follow-up visit with a physiotherapist at 4- to 6-month visit was 0.6 (SD 1.2) in the intervention group and 0.8 (SD 1.1) in the usual care group (adjusted P=.46).

A total of 33 smokers were included in the trial, 22 in the intervention group and 11 in the usual care group. At the 2-week follow-up, 64% (14/22) of smokers in the intervention group and 55% (6/11) of smokers in the usual care group reported being abstinent from smoking (adjusted P=.76). At 6 to 10 weeks, the numbers were 64% (14/22) vs 46% (5/11; adjusted P=.24), and at 12 to 14 months, they were 55% (12/22) vs 36% (4/11; adjusted P=.74), for the intervention and control groups, respectively.
Table 3. Secondary outcome measures at the 6- to 10-week follow-up.

| Characteristics                     | Intervention          | Usual care            | P value for difference crude | P value for difference adjusted<sup>b</sup> |
|--------------------------------------|-----------------------|-----------------------|-----------------------------|-------------------------------------------|
|                                      | Values                | Change from baseline  | Values                      | Change from baseline                     |                                           |
| Risk factors                         |                       |                       |                             |                                           |
| SBP<sup>c</sup> (mm Hg), mean (SD)   | 123.6 (14.8)          | –25.3 (27.4)          | 127.1 (13.3)                | –16.5 (27.4)                             | .08                                        |
|                                      |                       |                       |                             |                                           | .02                                        |
| DBP<sup>d</sup> (mm Hg), mean (SD)   | 75.3 (10.0)           | –13.4 (15.6)          | 77.8 (8.7)                  | –9.1 (13.4)                              | .11                                        |
|                                      |                       |                       |                             |                                           | .05                                        |
| BMI (kg/m<sup>2</sup>), median (IQR)| 26.3 (24.0 to 29.0)   | –0.3 (–1.1 to 0.3)    | 27.0 (24.3 to 29.9)         | –0.2 (–1.3 to 0.3)                       | .77                                        |
|                                      |                       |                       |                             |                                           | .39<sup>e</sup>                            |
| Total cholesterol (mmol/L), mean (SD)| 3.3 (0.8)             | –1.5 (1.1)            | 3.3 (0.6)                   | –1.6 (0.9)                               | .48                                        |
|                                      |                       |                       |                             |                                           | .37                                        |
| LDL<sup>f</sup>-cholesterol (mmol/L), mean (SD) | 1.5 (0.6) | –1.4 (0.9) | 1.5 (0.4) | –1.5 (0.8) | .28 | .24 |
| HDL<sup>g</sup>-cholesterol (mmol/L), median (IQR) | 1.1 (0.9 to 1.5) | 0.1 (–0.1 to 0.2) | 1.2 (1.0 to 1.5) | 0.1 (–0.1 to 0.3) | .80 | .93 |
| Triglycerides (mmol/L), median (IQR) | 1.0 (0.8 to 1.5)      | –0.3 (–0.8 to 0.0)    | 1.1 (0.8 to 1.4)            | –0.3 (–0.7 to 0.0)                       | .93                                        |
|                                      |                       |                       |                             |                                           | .99                                        |
| Fasting plasma glucose (mmol/L), median (IQR) | 6.1 (5.8 to 6.8) | –1.4 (–3.3 to –0.3) | 6.2 (5.6 to 7.0) | –0.9 (–2.8 to –0.2) | .81 | .47 |
| Self-reported parameters, mean (SD)  |                       |                       |                             |                                           |                                           |
| Vegetable consumption                | 2.2 (0.7)             | 0.3 (0.8)             | 2.2 (0.7)                   | 0.4 (1.1)                                | .74                                        |
|                                      |                       |                       |                             |                                           | .65                                        |
| Fruit consumption                   | 2.3 (0.7)             | 0.6 (1.0)             | 2.3 (0.7)                   | 0.5 (1.1)                                | .29                                        |
|                                      |                       |                       |                             |                                           | .36                                        |
| Fish consumption                    | 2.1 (1.0)             | 0.9 (1.1)             | 2.0 (0.9)                   | 0.8 (1.1)                                | .40                                        |
|                                      |                       |                       |                             |                                           | .18                                        |
| Consumption of sweets               | 2.3 (0.9)             | 0.3 (0.9)             | 2.3 (0.9)                   | 0.5 (1.1)                                | .27                                        |
|                                      |                       |                       |                             |                                           | .22                                        |
| Healthy diet index                  | 8.9 (2.0)             | 2.2 (2.3)             | 8.8 (1.7)                   | 2.1 (2.6)                                | .82                                        |
|                                      |                       |                       |                             |                                           | .77                                        |

<sup>a</sup>Numbers are presented as mean differences (SD), median differences (IQR), and <i>P</i> values. Crude and adjusted <i>P</i> values are shown for the differences in mean or median change (δ) between baseline and 6- to 10-week follow-up, comparing the intervention and usual care groups.

<sup>b</sup>Adjusted for gender, age, weight, previous heart disease, and smoking status at the time of the index event.

<sup>c</sup>SBP: systolic blood pressure.

<sup>d</sup>DBP: diastolic blood pressure.

<sup>e</sup>Not adjusted for weight.

<sup>f</sup>LDL: low-density lipoprotein.

<sup>g</sup>HDL: high-density lipoprotein.
Table 4. Secondary outcome measures at 12- to 14-month follow-up.\textsuperscript{a}

| Characteristics | Intervention | Usual care | \( P \) value for difference crude | \( P \) value for difference adjusted\textsuperscript{b} |
|----------------|-------------|------------|------------------------------------|-----------------------------------------------|
| Risk factors   |             |            |                                    |                                               |
| SBP\textsuperscript{c} (mm Hg), mean (SD) | 126.9 (16.0) | 126.5 (13.7) | \(-17.0\) (28.3) \( .22 \) | \( .09 \) |
| DBP\textsuperscript{d} (mm Hg), mean (SD) | 76.1 (10.9) | 75.7 (9.2)   | \(-11.3\) (17.1) \( .69 \) | \( .49 \) |
| BMI (kg/m\textsuperscript{2}), median (IQR) | 26.4 (23.6 to 30.1) | 27.1 (24.8 to 29.1) | 
| Total cholesterol (mmol/L), mean (SD) | 3.5 (0.9) | 3.5 (0.8) | \(-1.5\) (1.1) \( .41 \) | \( .30 \) |
| LDL\textsuperscript{f}-cholesterol (mmol/L), mean (SD) | 2.1 (1.0) | 2.0 (0.9) | \(-1.4\) (1.0) \( .20 \) | \( .21 \) |
| HDL\textsuperscript{g}-cholesterol (mmol/L), median (IQR) | 1.2 (1.0 to 1.5) | 1.3 (1.0 to 1.5) | 0.1 (0.0 to 0.3) \( .89 \) | \( .77 \) |
| Triglycerides (mmol/L), median (IQR) | 1.0 (0.7 to 1.4) | 1.2 (0.8 to 1.5) | \(-0.3\) (0.9 to 0.0) \( .48 \) | \( .98 \) |
| Fasting plasma glucose (mmol/L), median (IQR) | 6.0 (5.6 to 6.7) | 6.0 (5.5 to 6.5) | \(-1.5\) (3.3 to 0.2) \( .45 \) | \( .48 \) |
| HbA\textsubscript{1c}\textsuperscript{h} (mmol/mol), median (IQR) | 40.0 (36.0 to 43.0) | 38.0 (37.0 to 43.0) | 1.0 (0.0 to 0.3) \( .68 \) | \( .40 \) |

Self-reported parameters, mean (SD)

|                         | Intervention | Usual care | \( P \) value for difference crude | \( P \) value for difference adjusted\textsuperscript{b} |
|-------------------------|-------------|------------|------------------------------------|-----------------------------------------------|
| Vegetable consumption   | 2.1 (0.8)   | 2.0 (0.8)   | 0.3 (1.0) \( .67 \)               | \( .77 \) |
| Fruit consumption       | 2.0 (0.8)   | 2.2 (0.8)   | 0.3 (0.8) \( .92 \)               | \( .99 \) |
| Fish consumption        | 1.8 (1.1)   | 2.0 (0.9)   | 0.6 (1.0) \( .70 \)               | \( .66 \) |
| Consumption of sweets   | 2.3 (0.8)   | 2.1 (0.9)   | 0.4 (1.0) \( .45 \)               | \( .37 \) |
| Healthy diet index      | 8.2 (2.1)   | 8.2 (1.8)   | 1.6 (2.2) \( .69 \)               | \( .45 \) |

\( a \)Numbers are presented as mean differences (SD), median differences (q1, q3), and \( P \) values. Crude and adjusted \( P \) values are shown for the differences in mean or median change (\( \delta \)) between baseline and 12- to 14-month follow-up, comparing the intervention and usual care groups.

\( b \)Adjusted for gender, age, weight, previous heart disease, and smoking status at the time of the index event.

\( c \)SBP: systolic blood pressure.

\( d \)DBP: diastolic blood pressure.

\( e \)Not adjusted for weight.

\( f \)LDL: low-density lipoprotein.

\( g \)HDL: high-density lipoprotein.

\( h \)HbA\textsubscript{1c}: glycated hemoglobin A\textsubscript{1c}. 
Uptake and Adherence

Attendance to the cardiac rehabilitation program was generally high. A total of 93% (93/100) of patients in the intervention group attended the first follow-up visit with a physiotherapist, and 71% (71/100) attended the second. The corresponding percentages for the usual care group were 98% (48/49) and 86% (42/49). However, only 66% (66/100) of patients in the intervention group and 82% (40/49) of patients in the usual care group performed a submaximal exercise test at both visits.

A total of 92% (92/100) of patients in the intervention group attended the 6- to 10-week follow-up and 96% (96/100) attended the 12- to 14-month follow-up, and the corresponding numbers for the usual care group were 98% (48/49) for both follow-up visits.

Uptake to the web application was 86.1% (87/101). Adherence (the proportion of the 87 patients who continued to log data at least twice per week) declined during the trial period, from its highest of 91% (79/87) at week 1 to 56% (49/87) at week 25 (Figure 6).
The most frequent parameters to be logged to the web-based application by patients in the intervention group were intake of medication and consumption of vegetables, followed by physical activity (Multimedia Appendix 1).

**Additional Analysis**

There was no difference in the frequency of deaths due to any cause (n=1 in each group, $P=0.62$). The frequencies of rehospitalizations during the 12- to 14-month follow-up period were also similar among the groups. In total, 22% (22/100) of the patients in the intervention group and 27% (13/49) of the patients in the usual care group were rehospitalized due to any cause ($P=0.58$), and 8% (8/100) versus 4% (2/49) of the patients were hospitalized due to ischemic heart disease ($P=0.35$).

**Discussion**

**Principal Findings**

In our study, evaluating the effects of a web-based application as an addition to usual care cardiac rehabilitation as compared with usual care alone, we found that there was a trend toward better exercise capacity in the intervention group; however, this was not statistically significant. On the other hand, the patients receiving access to the web-based application had a significantly reduced SBP at the first 2 follow-up visits, a reduced DBP at the second follow-up visit, and an initial increase in intake of fish and fruit. Although cardiac rehabilitation attendance was high in both groups, adherence to the web-based application declined over time.

After the baseline exercise test, all patients in our study received individualized physical activity recommendations and an individualized exercise prescription and were invited to participate in exercise-based cardiac rehabilitation based at the cardiac rehabilitation center. Those in the intervention group were, in addition, advised to rate their perceived exertion and time spent in exercise and log the information on the web-based application, after which they would receive automated positive feedback. Although attendance to physiotherapy follow-up visits was high, not all patients completed the submaximal exercise tests. The reasons for noncompletion were not officially documented, but according to clinical experience, reasons often include common cold, leg or joint pain, and perceived inability to exercise. During follow-up, both groups had a significant improvement in submaximal exercise capacity and, although not significant, there was a 4.1 W difference among the groups in favor of the intervention group. Increased physical activity levels using telehealth in cardiac rehabilitation have been demonstrated in previous studies. A recent meta-analysis showed that this applied especially to studies where telehealth was used as an adjunct to comprehensive cardiac rehabilitation [16]. The web-based application in our study did not specifically provide feedback on adherence to the exercise-based cardiac rehabilitation program but rather to increase physical activity levels in general, which may perhaps partly explain the lack of significant differences in exercise capacity among the groups.

The benefit of the combination of involvement of health care professionals with eHealth has been shown to be beneficial in studies addressing cardiovascular risk factors [31-33]. For example, a recent RCT found that participants using an
exercise-focused smartphone app had better fitness levels (measured by maximal oxygen consumption or VO2peak) compared with usual care after a follow-up at the 1-year postcardiac rehabilitation [32]. The information that participants logged into the smartphone app was monitored by a physiotherapist who provided personal feedback. Adherence to the smartphone app was high, and participants felt that they reported to an individual involved in their care rather than a database or a robot. This knowledge can be used in the design of future studies aiming to increase the exercise-based cardiac rehabilitation adherence with the overall aim of increasing patients’ physical fitness.

Most patients who had an MI were already on a regime of cardioprotective medication when discharged from the hospitals (Table 1). Despite this, a significant difference in BP control was observed among the groups, in favor of the intervention group. In our crude analysis, patients in the intervention group had a significantly larger SBP decrease between baseline and the 2-week follow-up. A numerical but nonsignificant difference among the groups then remained throughout the trial period. After adjusting for relevant covariates, the observed differences in BP control increased, in favor of the intervention group, and included a significant difference in SBP and DBP decrease between baseline and the 6- to 10-week follow-up. Patients in the intervention group achieved an 11.3 mm Hg larger decrease in SBP between baseline and the 2-week follow-up compared with patients in the usual care group, the difference being 8.8 mm Hg at the 6 to 10-week follow-up and 7.0 mm Hg at the 12- to 14-month follow-up. The choice of covariates was based on observed differences in baseline characteristics, which indicated a higher comorbidity in the intervention group. As such, not adjusting for baseline differences could have masked a difference among the groups. Hypertension is a predominant risk factor for CHD morbidity and mortality [7]. Previous meta-analyses have shown that a 10 mm Hg reduction in SBP reduces the risk of future CHD events by 22%, irrespective of the method of BP reduction [34]. Given the magnitude of the observed decrease in BP in our study, the difference is likely to have some clinical benefit. An improvement in reaching BP goals when having access to a web-based application as an aid in cardiac rehabilitation is in line with previous studies [11-13,20,35]. For example, Widmer et al [35] also demonstrated a substantial BP difference, with patients who after a percutaneous coronary intervention received digital health intervention (web-based or smartphone-based) as a complement to traditional cardiac rehabilitation having significant improvements in SBP (−10.8 mm Hg, P<.001 vs −6.1 mm Hg, P=.36) at a 3-month follow-up. Because intake of medication was the most frequently logged parameter in the web-based application, one possible reason for improved BP values in the intervention group might be an increased compliance to antihypertensive medication. Increased adherence to medication has been demonstrated in a previous study on a web-based application in cardiac rehabilitation [36]. In addition, increased patient engagement with self-monitoring has been shown to improve BP control [37,38]. The difference in BP among the groups declined throughout the trial period. One reason might be that adherence to behavioral recommendations has been seen to decline over time in cardiac rehabilitation, or it could have something to do with decreasing adherence to the web-based application which is a known methodological challenge within eHealth [11,39]. As there was no measurement done at the end of the 25-week intervention period, we do not know exactly when the differences attenuated.

We also observed a significant beneficial effect on healthy dietary choices. During the first 2 weeks of follow-up, patients in the intervention group had a significantly higher score on the health diet index and higher intake of fish and fruit. Following a healthy diet rich in healthy oils and plant-based food has been shown to reduce cardiovascular events [40]. Previous studies on eHealth in cardiac rehabilitation have shown both improvement and no effect on dietary habits [15,16,41]. Here, the data were self-reported, which has considerable limitations, and the results should be interpreted with caution [42].

Smoking is a leading cause of preventable death globally and is a strong risk factor for CHD [7]. There was a numerical difference in the number of smokers who reported being abstinent at the follow-up visits, but owing to the low number of smokers in our study population, the differences were not statistically significant. In addition, whether the numerical difference was due to the intervention or chance finding cannot be stated. However, telehealth interventions in cardiac rehabilitation have been shown to reduce the likelihood of smoking by 23%, giving promise to using eHealth as a tool to tackle this important risk factor [16].

**Adherence to eHealth**

eHealth has the potential to improve participation and adherence to cardiac rehabilitation programs by including patients more actively in their own care and increasing flexibility and accessibility [21]. In our study, although uptake to the web-based application was high, adherence declined over time, with just over half of the users logging data at least twice weekly at the end of the 25-week intervention period. The main reason for limiting the intervention time to 25 weeks was to harmonize the intervention length with usual care, as most usual care cardiac rehabilitation interventions take place during the first 6 months after MI (nurse and physiotherapist visits, exercise training sessions, and patient education). In addition, patients usually have the highest level of motivation for lifestyle changes during the first months after MI [39]. The last reason was that adherence to eHealth interventions in cardiac rehabilitation has been shown to attenuate over time (weeks to months) [11,43].

In our study, reported reasons for stopping the use of the web-based application were mostly related to stress, some experienced a lack of feedback and some experienced too much feedback. User attrition in studies on eHealth is a well-known methodological challenge, with attrition rates reaching up to 60% to 80% [43]. High attrition rates can make it difficult to measure an intervention’s effect and subsequently threaten both internal and external study validity [44,45]. Van der Mispel et al [44] studied user and website characteristics related to attrition. They demonstrated that attrition was higher for men and younger adults, as well as for less interactive components of the studied application. Buys et al [46] reported a general interest in technology-enabled home-based cardiac rehabilitation.
among patients with cardiovascular disease. Their study demonstrated that patients with different characteristics were interested in different types of technology-based cardiac rehabilitation; for example, older patients were more interested in web-based options, and younger patients were more interested in app-based cardiac rehabilitation. They also looked at which parts of cardiac rehabilitation patients wanted to have technology-based options, including ideas on exercise, healthy meals, and stress management. This indicates that even if technology-based cardiac rehabilitation aims to make traditional programs more flexible and individualized, even the technology platforms need to be adjusted to individual needs for optimum effect.

**Strengths and Limitations**

In our study, we used data collected through standardized protocols from the SWEDHEART registry [9,47]. The registry is well established in Swedish cardiac rehabilitation centers and is used daily by personnel. At the time of the study, SWEDHEART nationwide coverage was >75%, registering eligible cases from 97% of Swedish hospitals. Data quality is regularly monitored, showing >95% agreement with data from hospital records [48]. Using SWEDHEART prespecified time points for follow-up and procedures provided a standardization, which otherwise can be a challenge in multicenter trials. Cardiac rehabilitation program attendance was high, and few participants were lost on follow-up.

The study was unblinded. Although blinding is preferred in RCTs, it is difficult to blind patients and health care providers in eHealth interventions. The follow-up data do not include information on the use of commercial web-based applications by the patients in the usual care group. The age limit considered in this study may restrict generalizability to all age groups. There might have been some selection bias, where more motivated patients would be more likely to agree to participate in a study using digital technology, requiring active participation. When interpreting the results, one should keep in mind the potential sources of inaccuracy in point BP measurements, which is a known source of bias in the clinical setting [49].

**Conclusions**

Digital technologies provide new opportunities in health care. Our results add to existing evidence and suggest that complementing comprehensive cardiac rehabilitation programs with a web-based application may positively affect risk factor outcomes and lifestyle, including BP and dietary choices. In addition, web-based technologies can be used to make cardiac rehabilitation programs more flexible and individualized, but further efforts should be invested to find ways to improve patient adherence to the platforms.

**Acknowledgments**

The study was funded by the Faculty of Medicine at Lund University, The Department of Coronary Care at Skåne University Hospital Centre of Excellence in Skåne Funds, and Avtal om Läkarutbildning och Forskning Grants County Council of Västerbotten. This study was partially sponsored by Cross Technology Solutions AB. The funding party had no role in design of the study, analysis of data, or writing of the manuscript.

**Conflicts of Interest**

None declared.

**Multimedia Appendix 1**

Percentage of reports per parameter in the web-based application.

[DOCX File, 16 KB-Multimedia Appendix 1]

**Multimedia Appendix 2**

CONSORT-eHEALTH checklist (V 1.6.1).

[PDF File (Adobe PDF File), 1222 KB-Multimedia Appendix 2]

**References**

1. Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease. Circ Cardiovas Qual Outcomes 2019 Jun;12(6):e005375. [doi: 10.1161/circoutcomes.118.005375]
2. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe--epidemiological update 2015. Eur Heart J 2015 Oct;36(40):2696-2705. [doi: 10.1093/eurheartj/ehv428] [Medline: 26306399]
3. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kotkte TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007 Jun 07;356(23):2388-2398. [doi: 10.1056/nejmsa053935]
4. Ambrosetti M, Abreu A, Corrà U, Davos C, Hansen D, Frederix I, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 2020 Apr 07:2020. [doi: 10.1177/2047487320913379] [Medline: 33611446]
5. Wood D, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008 Jun;371(9629):1999-2012. [doi: 10.1016/s0140-6736(08)60868-5]

6. Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason-Wehrens B, Cupples M, et al. Secondary prevention in the clinical management of patients with cardiovascular disease. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiology rehabilitation section of the European Association for Cardiovascular Prevention and Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014 Jun 20;21(6):664-681. [doi: 10.1177/2047487314495972] [Medline: 22718797]

7. Piepoli MF. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Int J Behav Med 2017 Jun 13;24(3):321-419. [doi: 10.1007/s12529-016-9583-6] [Medline: 28290077]

8. Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016 Apr;23(6):636-648. [doi: 10.1177/2047487315569401] [Medline: 25687109]

9. Jernberg T, Boberg B, Bäck M, Dahlbom L, Erlinge D, Friberg O. SWEDHEART Årsrapport 2019. Uppsala Clinical Research Center, UCR. 2020. URL: https://www-ucr-uu-se.translate.goog/swedheart/arsrapport? x_tr_sl=sv& x_tr_tl=en& x_tr_hl=en& x_tr_pto=sc [accessed 2022-02-11]

10. Michelsen HO, Sjölin I, Schlyter M, Hagström E, Kiessling A, Henriksson P, et al. Cardiac rehabilitation after acute myocardial infarction in Sweden - evaluation of programme characteristics and adherence to European guidelines: the Perfect Cardiac Rehabilitation (Perfect-CR) study. Eur J Prev Cardiol 2020 Jan 26;27(1):18-27. [doi: 10.1177/2047487319856579] [Medline: 31349776]

11. Blasco A, Carmona M, Fernández-Lozano I, Salvador C, Pascual M, Sagredo P, et al. Evaluation of a telemedicine service for the secondary prevention of coronary artery disease. J Cardiopulm Rehabil Prev 2012;32(1):25-31. [doi: 10.1097/HCR.0b013e3182343aa7] [Medline: 22113368]

12. Pietrzak E, Cotea C, Pullman S. Primary and secondary prevention of cardiovascular disease: is there a place for Internet-based interventions? J Cardiopulm Rehabil Prev 2014;34(5):303-317. [doi: 10.1097/HCR.0000000000000663] [Medline: 25079147]

13. Varnfield M, Karunanithi M, Lee C, Honeyman E, Arnold D, Ding H, et al. Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomised controlled trial. Heart 2014 Nov 27;100(22):1770-1779 [FREE Full text] [doi: 10.1136/heartjnl-2014-305783] [Medline: 24973083]

14. Neubeck L, Redfern JU, Fernandez R, Briffa T, Bauman A, Freedman SB. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. Eur J Cardiovasc Preven Rehabil 2009 Jun;16(3):281-289. [doi: 10.1097/HCR.0b013e3282a4e7a]

15. Brors G, Pettersen TR, Hansen TB, Fridlund B, Holvold LB, Lund H, et al. Modes of e-Health delivery for the secondary prevention of coronary artery disease: a systematic review. BMC Health Serv Res 2019 Jun 10;19(1):364 [FREE Full text] [doi: 10.1186/s12913-019-4106-1] [Medline: 31182100]

16. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B, et al. Telhealth interventions for the secondary prevention of coronary heart disease: an evidence synthesis. Eur J Cardiovasc Nurs 2019 Apr 22(4):260-271. [doi: 10.1177/1475515119826510] [Medline: 30667278]

17. Burke LE, Ma J, Azar KM, Bennett GG, Peterson ED, Zheng Y, et al. Current science on consumer use of mobile health for cardiovascular disease prevention. Circulation 2015 Sep 22;132(12):1157-1213. [doi: 10.1161/circ.108.0000000000000023]

18. Beatty AL, Fukuoka Y, Whoolea MA. Using mobile technology for cardiac rehabilitation: a review and framework for development and evaluation. J Am Heart Assoc 2013 Nov 18;2(6):e000568. [doi: 10.1161/jaha.113.000568]

19. Widmer RJ, Senecal C, Allison TG, Lopez-Jimenez F, Lerman LO, Lerman A. Dose-response effect of a digital health intervention during cardiac rehabilitation: subanalysis of randomized controlled trial. J Med Internet Res 2020 Feb 26;22(2):e13055 [FREE Full text] [doi: 10.2196/13055] [Medline: 32130116]

20. Indraratna P, Tardor D, Yu J, Delbaere K, Brodie M, Lovell N, et al. Mobile phone technologies in the management of ischemic heart disease, heart failure, and hypertension: systematic review and meta-analysis. JMRI Mhealth Uheath 2020 Jul 06;8(7):e16695 [FREE Full text] [doi: 10.2196/16695] [Medline: 32628615]

21. Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Böhm A, et al. ESC e-Cardiology Working Group Position Paper: overcoming challenges in digital health implementation in cardiovascular medicine. Eur J Prev Cardiol 2019 Jul 27;26(11):1166-1177. [doi: 10.1177/2047487319832394] [Medline: 30917695]

22. Gonzalez M, Sjölin I, Bäck M, Michelsen HO, Tanha T, Sandberg C, et al. Effect of a lifestyle-focused electronic patient support application for improving risk factor management, self-rated health, and prognosis in post-myocardial infarction patients: study protocol for a multi-center randomized controlled trial. Trials 2019 Jan 24;20(1):76 [FREE Full text] [doi: 10.1186/s13063-018-3118-1] [Medline: 30678709]
23. De Schutter A, Kachur S, Lavie C, Menezes A, Shum K, Bangalore S, et al. Cardiac rehabilitation fitness changes and subsequent survival. Eur Heart J Qual Care Clin Outcomes 2018 Jul 01;4(3):173-179. [doi: 10.1093/ehjqcco/qey018] [Medline: 29701805]

24. SWEDHEART Annual Report 2020. Uppsala Clinical Research Centre. 2020. URL: https://www.ucr.uu.se/swedeheart/ [accessed 2022-02-11]

25. No authors listed. Exercise tests in relation to cardiovascular function. Ann Intern Med 1968 Sep 01;69(3):652. [doi: 10.7326/0003-4819-69-3-652_2]

26. Michelsen S. Reproducibility of cumulative work, heart rate and blood pressure response during stepwise versus continuous load increment during a maximal bicycle ergometer test. Scand J Clin Lab Invest 1990 Jun 08;50(4):409-415. [doi: 10.3109/003655190091901599] [Medline: 2392654]

27. Borg G. Borg's Perceived Exertion and Pain Scales. Champaign, Illinois: Human Kinetics; 1998.

28. Nationella Riktlinjer för Prevention Och Behandling Vid Ohälsosamma Levnadsanor - Stöd för Styrning Och Ledning. Stockholm: Socialstyrelsen; 2018:470-491.

29. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007 Aug 28;116(9):1081-1093. [doi: 10.1161/circulationaha.107.185649]

30. Grimby G, Frändin K. On the use of a six-level scale for physical activity. Scand J Med Sci Sports 2018 Mar 17;28(3):819-825. [doi: 10.1111/smss.12991] [Medline: 29027263]

31. Green BB, Cook AJ, Ralston JD, Catz SL, Carlson J, et al. Effectiveness of home blood pressure monitoring, web communication, and pharmacist care on hypertension control: a randomized controlled trial. J Am Med Assoc 2008 Jun 25;299(24):2857-2867 [FREE Full text] [doi: 10.1001/jama.299.24.2857] [Medline: 1857730]

32. Lunde P, Bye A, Bergland A, Grimsmo J, Jarstad E, Nilsson BB. Long-term follow-up with a smartphone application improves exercise capacity post cardiac rehabilitation: a randomized controlled trial. Eur J Prev Cardiol 2020 Nov 28;27(16):1782-1792 [FREE Full text] [doi: 10.1177/2047487320905717] [Medline: 32106713]

33. Widmer RJ, Allison TG, Lennon R, Lopez-Jimenez F, Lerman LO, Lerman A. Digital health intervention during cardiac rehabilitation: a randomized controlled trial. Am Heart J 2017 Jun;188:65-72. [doi: 10.1016/j.ahj.2017.02.016] [Medline: 28577682]

34. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009 May 19;338(may19 1):b1665 [FREE Full text] [doi: 10.1136/bmj.b1665] [Medline: 19454737]

35. Widmer RJ, Allison TG, Lerman LO, Lerman A. Digital health intervention as an adjunct to cardiac rehabilitation reduces cardiovascular risk factors and rehospitalizations. J Cardiovasc Transl Res 2015 Jul 7;8(5):283-292 [FREE Full text] [doi: 10.1007/s12265-015-9629-1] [Medline: 25946990]

36. Johnston N, Bodgard J, Jerström S, Åkesson J, Brosson H, Alfredsson J, et al. Effects of interactive patient smartphone support app on drug adherence and lifestyle changes in myocardial infarction patients: a randomized study. Am Heart J 2016 Aug;178:85-94 [FREE Full text] [doi: 10.1016/j.ahj.2016.05.005] [Medline: 27502855]

37. McCartney DE, McManus RJ. Self-monitoring and self-management. Curr Opin Nephrol Hypertens 2016;25(6):502-507. [doi: 10.1097/MDM.0000000000000279]

38. Ulhig K, Patel K, Ip S, Kissios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med 2013 Aug 06;159(3):185-194 [FREE Full text] [doi: 10.7326/0003-4819-159-3-201308060-00008] [Medline: 23922064]

39. Andrikopoulos G, Tzeis S, Nikas N, Richter D, Pipilis A, Gotsis A, et al. Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome -results from the countrywide TARGET study. Int J Cardiol 2013 Sep 30;168(2):322-927. [doi: 10.1016/j.ijcard.2012.10.049] [Medline: 23186596]

40. Estruch R, Ros E, Salas-Salvadó J, Covas M, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013 Apr 04;368(14):1279-1290. [doi: 10.1056/nejmoa1200303]

41. Lear S, Singer J, Banner-Lukaris D, Horvat D, Park J, Bates J, et al. Improving access to cardiac rehabilitation using the internet: a randomized trial. Stud Health Technol Inform 2015;209:58-66. [Medline: 25980706]

42. Warren JM, Ekelund U, Besson H, Mezzani A, Geladas N, Vanhees L. Assessment of physical activity – a review of methodologies with reference to epidemiological research: a report of the exercise physiology section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010 Apr;17(2):127-139. [doi: 10.1097/hjr.0b013e32832ed875]

43. Geraghty AW, Torres LD, Leykin Y, Pérez-Stable EJ, Muñoz RF. Understanding attrition from international Internet health interventions: a step towards global eHealth. Health Promot Int 2013 Sep 10;28(3):442-452 [FREE Full text] [doi: 10.1093/heapro/das029] [Medline: 22786673]

44. Van der Mispel C, Poppe L, Crombez G, Verloigne M, De Bourdeaudhuij I. A self-regulation-based ehealth intervention to promote a healthy lifestyle: investigating user and website characteristics related to attrition. J Med Internet Res 2017 Jul 11;19(7):e241 [FREE Full text] [doi: 10.2196/jmir.7277] [Medline: 28698168]
Abbreviations

BP: blood pressure
CHD: coronary heart disease
DBP: diastolic blood pressure
LDL: low-density lipoprotein
MI: myocardial infarction
RCT: randomized controlled trial
SBP: systolic blood pressure
SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials
SWEDEHEART: Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies